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Abstract
Anti-Saccharomyces cerevisiae antibodies (ASCA) have
been described as specific markers in Crohn’s disease
and their healthy first-degree relatives. 171 patients with
Crohn’s disease, their 105 first-degree relatives, 145 pa-
tients with ulcerative colitis and 101 first-degree relatives
of patients with ulcerative colitis, 50 patients with infec-
tious enterocolitis and 100 healthy controls were tested
for ASCA employing the ELISA technique. When com-
pared with the healthy controls (p ! 0.0001) and patients
with infectious enterocolitis (p ! 0.0001) the prevalence
of ASCA was significantly increased in patients with
Crohn’s disease and their first-degree relatives (p ! 0.01).
Further significant differences concerning the frequency
of ASCA within the different groups of our study popula-
tion were not observed. In particular, ASCA were not
found in increased prevalence in infectious enterocolitis.
These observations are compatible with a role of ASCA
as a marker of genetic predisposition to Crohn’s dis-
ease.
Copyright © 2002 S. Karger AG, Basel
Introduction
In patients with inflammatory bowel diseases, various
autoantibodies, such as perinuclear antineutrophilic cyto-
plasmatic antibodies (pANCA), antibodies against exo-
crine pancreas (PAK), colonic epithelial cells, intestinal
goblet cells and endothelial cells have been described in
recent years [1–15]. Apart from the differentiation be-
tween Crohn’s disease and ulcerative colitis in rare cases
of undetermined colitis, in particular the pathophysiolog-
ic importance of these serological markers remains to be
elucidated. In view of the current literature it is unlikely
that autoantibodies are involved in the pathophysiology
of Crohn’s disease or ulcerative colitis, e.g. by mediating
cytotoxicity against colonic epithelial cells. Rather, they
are the result of a cross-reactivity between the respective
target antigen (or tissue) used for their detection via indi-
rect immunofluorescence or ELISA and yet undeter-
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mined luminal antigens. Moreover, for some autoanti-
bodies familial clustering has been described, which
means that the respective autoantibody was not only
present in patients with inflammatory bowel disease but
although in their healthy first-degree relatives who display
a 10- to 15-fold increased risk to develop either Crohn’s
disease or ulcerative colitis throughout their lifetime.
These observations are compatible with a role of the
respective autoantibody as a genetic marker of inflamma-
tory bowel disease. The latter assumption is further sup-
ported if the prevalence of the respective autoantibody
was not enhanced in patients with infectious enterocolitis.
To the best of our knowledge, with the exception of endo-
thelial cell autoantibodies previously described by our
group [10], this was the case for all other autoantibodies
with familial occurrence. These findings additionally ar-
gue against a role of the different autoantibodies as an
environmental marker, which might become positive if
individuals share the same environment, but rather it is
compatible with a role as a genetic marker. In accordance
with this hypothesis, pANCA were repeatedly described
as useful tools to delineate genetically homogeneous sub-
groups of patients with inflammatory bowel disease [16,
17].
Recently, anti-Saccharomyces cerevisiae antibodies
(ASCA), which are directed against oligomannosidic epi-
topes within the cell wall of yeast cells, have been
described in 40–70% of patients with Crohn’s disease
[18–20]. Like other autoantibodies, ASCA have been
described in 20–25% of unaffected first-degree relatives
of patients with Crohn’s disease [21–24]. Yeast cells are a
part of the normal intestinal flora. Yeasts are also widely
used for production of food as bread and beer and thus
come into contact with the intestinal epithelium and the
intestinal mucosal immune system. The present study was
performed retrospectively to assess the frequency of
ASCA in patients with Crohn’s disease, ulcerative colitis
and two separate cohorts of healthy first-degree relatives
of patients with inflammatory bowel disease. In order to
clarify whether these autoantibodies are genetic or envi-
ronmental markers of disease susceptibility, their preva-
lence was additionally investigated in patients with differ-
ent forms of infectious enterocolitis.
Methods
Study Population
171 sera from patients with Crohn’s disease and 145 sera from
patients with ulcerative colitis were tested for ASCA IgA and IgG.
The diagnosis was based on conventional clinical, radiological, endo-
scopic and histological criteria and cases with undetermined colitis
were excluded. Additionally, 105 sera from first-degree relatives of
45 patients within the group of patients with Crohn’s disease and 101
sera from first-degree relatives of 35 patients within the group of
patients with ulcerative colitis were investigated. Only healthy first-
degree relatives without clinical signs of inflammatory bowel disease
were included. The latter were assessed by employing a standardized
questionnaire. The first control group consisted of 100 sera from
healthy, unrelated controls. The second control group comprised 50
patients with infectious enterocolitis (giardiasis, 15 cases; amebiasis,
13 cases; infection with campylobacter, 13 cases; infection with sal-
monella, 9 cases). The characteristics of the study population are
depicted in table 1. The study protocol had been approved by the
local ethics committee.
ASCA ELISA
Sera of patients and controls were tested for both ASCA IgA and
IgG using Medizym® ASCA IgA and Medizym® ASCA IgG ELISA
kits from Medipan Diagnostica, Selchow, Germany. 100 Ìl of serum
and control samples diluted 1/51 in the ready-for-use diluent was
added to the 96-well microtiter plates coated with the specific antigen
(mannan from S. cerevisiae). The plates were covered and incubated
for 60 min at 37°C. The unbound serum components were removed
and the plates were washed 5 times with 300 Ìl of washing buffer.
100 Ìl of anti-human IgA or IgG antibodies conjugated with horse-
radish peroxidase were added, which reacted with the antibodies
bound specifically to the antigen. After incubation for 30 min at
37°C the unbound conjugates were removed and the plates were
Table 1. Characteristics of the study population
Crohn’s
disease
Ulcerative
colitis
First-degree relatives
of patients with
Crohn’s disease ulcerative colitis
Infectious
enterocolitis
Healthy
controls
Number 171 145 105 101 50 100
Male/female ratio 63/108 71/74 55/50 51/50 22/28 57/43
Age, years
Mean B SD 39.8B13.8 42.4B12.8 31B8 36B9 34B11 39B12
Range 16U76 17U76 19U69 17U61 4U57 20U61
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washed 5 times with 300 Ìl of washing buffer. Then 100 Ìl of sub-
strate (3,3),5,5)-tetramethylbenzidine in citrate buffer with hydrogen
peroxide) were added. The plates were incubated for 10 min at room
temperature in the dark and the enzyme reaction was stopped by
adding 100 Ìl of stop solution (0.25 M sulfuric acid for IgA, 1 M
sulfuric acid for IgG). The plates were read at 450 nm using a micro-
plate reader (Tosoh Corp., Tokyo, Japan). Diluted human sera pro-
vided by the manufacturer served as internal controls. In the case of
the IgA assay, four calibrators were used (20, 40, 70, 300 U/ml), in
the case of the IgG assay three control samples (ASCA IgG-positive
control, ASCA IgG-negative control, ASCA IgG cut-off control).
For qualitative evaluation the binding index (BI = ODsample/
ODcut-off control) was calculated. The cut-off control for the IgA assay
was the 20 U/ml calibrator. The sample was considered positive at a
BI 61.0. Additionally, the IgA assay was evaluated quantitatively by
calculation of a standard curve from the four calibrators. The sample
was considered positive for calculated at values 620 U/ml. For every
sample, two analyses on the same plate were carried out. Statistical
analysis was performed using ¯2 test and Fisher’s exact test.
Results
When compared with the healthy controls (p ! 0.0001)
and patients with infectious enterocolitis (p ! 0.0001), the
ASCA frequency was significantly increased in patients
with Crohn’s disease regardless of the IgA or IgG type of
ASCA. In first-degree relatives of patients with Crohn’s
disease, only the IgA (p ! 0.05) or the combination of the
IgA and IgG type (p ! 0.01) of ASCA was found in
increased frequency in comparison with the healthy con-
trols. Separate and combined frequencies of ASCA IgA
and IgG are given in table 2 and 3, respectively. The
ASCA status was compared between first-degree relatives
of ASCA-positive index patients and ASCA-positive rela-
tives of ASCA-negative index patients with Crohn’s dis-
ease. However, a significant difference between these
Table 2. Frequencies of ASCA IgA and IgG in patients with Crohn’s disease and ulcerative colitis and their unaf-
fected first-degree relatives compared with those frequencies observed in the healthy controls (a) and patients with
infectious enterocolitis (b)
IgA (%) p value IgG (%) p value
Patients with Crohn’s disease (n = 171) 77 (45.0%) !0.0001a
!0.0001b
70 (40.9%) !0.0001a
!0.0001b
First-degree relatives of patients with
Crohn’s disease (n = 105)
13 (12.4%) !0.05a
n.s.b
5 (4.8%) n.s.a
n.s.b
Patients with ulcerative colitis (n = 145) 9 (6.2%) n.s.a
n.s.b
5 (3.4%) n.s.a
n.s.b
First-degree relatives of patients with
ulcerative colitis (n = 101)
3 (3.0%) n.s.a
n.s.b
2 (2.0%) n.s.a
n.s.b
Healthy controls (n = 100) 3 (3.0%) 3 (3.0%)
Patients with infectious enterocolitis (n = 50) 2 (4.0 %) 2 (4.0%)
Table 3. Combined frequencies of ASCA IgA and IgG in patients with Crohn’s disease and ulcerative colitis and their
unaffected first-degree relatives compared with those frequencies observed in the healthy controls (a) and patients
with infectious enterocolitis (b)
IgA and IgG
(%)
p value IgA or IgG
(%)
p value
Patients with Crohn’s disease (n = 171) 55 (32.2%) !0.0001a
!0.0001b
93 (54.4%) !0.0001b
!0.0001b
First-degree relatives of patients with
Crohn’s disease (n = 105)
1 (1.0%) n.s.a
n.s.b
17 (16.2%) !0.01a
n.s.b
Patients with ulcerative colitis (n = 145) 0 (0%) n.s.a
n.s.b
14 (9.7%) n.s.a
n.s.b
First-degree relatives of patients with
ulcerative colitis (n = 101)
0 (0.0%) n.s.a
n.s.b
5 (5.0%) n.s.a
n.s.b
Healthy controls (n = 100) 2 (2.0%) 4 (4.0%)
Patients with infectious enterocolitis (n = 50) 1 (2.0 %) 3 (3.0%)
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Table 4. Comparison of ASCA status of the patients with Crohn’s
disease and their first-degree relatives
First-degree
relatives
ASCA+
First-degree
relatives
ASCA–
™
Patients ASCA+ 8 38 46
Patients ASCA– 9 50 59
™ 17 88 105
The p value, which was calculated for the ASCA+ relatives of
ASCA+ patients against the ASCA+ relatives of ASCA– patients, was
not significant.
groups was not observed. Moreover, correlation of ASCA
titers between ASCA-positive relatives and the respective
index patient was not observed. Further significant differ-
ences concerning the frequency of ASCA within the dif-
ferent groups of our study population were not observed
(table 4).
Discussion
When compared with the two control groups, ASCA
were found in significantly increased frequency in pa-
tients with Crohn’s disease (54.4%) and in their healthy
first-degree relatives (16.2%), whereas this was not the
case in patients with ulcerative colitis and their healthy
first-degree relatives [21–24]. These findings confirm the
results of previous studies which described ASCA to be
associated with Crohn’s disease but not ulcerative colitis
and which found a familial occurrence of ASCA. How-
ever, the frequencies demonstrated herein are somewhat
lower than those described by other groups. In the study
of Seibold et al. [22], the frequencies of ASCA were 68%
in patients with Crohn’s disease and 25% in their first-
degree relatives. In addition, other groups also found
higher frequencies in patients with Crohn’s disease and
their first-degree relatives than described in our study [21,
23, 24]. Apart from ethnic differences, this might at least
in part be explained by methodical reasons. In the study
by Vermeire et al. [25], four different ASCA ELISA tests
were compared. The range in sensitivity was 41–76% and
the specificity ranged between 88.5 and 97.5%. The
assays used in the present study (Medipan) had the lowest
sensitivity (41%), but the highest specificity (97.5%) when
compared with other commercially available assays. The
comparably high specificity might be of importance if
ASCA are employed in order to differentiate between
ulcerative colitis and Crohn’s disease which is confined to
the colon. However, similar to other autoantibodies, such
as pANCA [1] or antibodies against exocrine pancreas [9],
the value of ASCA for the differential diagnosis between
Crohn’s disease and ulcerative colitis is limited by an
insufficient sensitivity. The increased occurrence of
ASCA in first-degree relatives of patients with Crohn’s
disease is compatible with a role of these antibodies as a
marker of genetic disease susceptibility, because relatives
of patients with inflammatory bowel disease are prone to
develop Crohn’s disease or ulcerative colitis. Based on our
findings and literature data it appears unlikely that ASCA
are the result of environmental antigenic stimuli. This
conclusion is supported by the comparable low ASCA
prevalence in the group of patients with infectious entero-
colitis, which served as a second control group. Why
ASCA similar to other autoantibodies display a familial
occurrence remains to be elucidated. An increased perme-
ability of the bowel wall has been described not only in
patients with Crohn’s disease and their healthy first-
degree relatives, but also in spouses of patients [26, 27].
Thus, a facilitated contact of antigens from yeast antigens
occurring in nutriments might be an explanation for gen-
eration of ASCA. On the other hand, in the study by Ver-
meire et al. [24], intestinal permeability was significantly
enhanced in patients with Crohn’s disease, but the latter
was not associated with the ASCA status of the respective
patients. Thus, ASCA and increased permeability are
most likely independent phenomena. Moreover, a famil-
ial aggregation of ASCA as observed in our study is not a
unique feature of inflammatory bowel disease but can also
be found in patients with diabetes mellitus and their rela-
tives [28]. Thus, it remains unclear whether ASCA are
pathogenic per se or only a specific phenomenon accom-
panying a subset of Crohn’s disease. To answer this ques-
tion it would be important to identify the antigen recog-
nized by ASCA within the small bowel, which is currently
unknown.
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